DDInter1397 DDInter1508
Paroxetine is a selective serotonin reuptake inhibitor (SSRI) drug commonly known as Paxil. It has a variety of uses, including the treatment of anxiety disorders, major depression, posttraumatic stress disorder, and symptoms of menopause, among others. It was approved by the FDA in the early 1990s and marketed by SmithKline Beecham.[L7712,L7715] A unique feature of this drug is that it is highly potent and selective in its inhibition of serotonin reuptake and has little effect on other neurotransmitters. Because of its potent inhibition of serotonin reuptake, paroxetine is more likely to cause withdrawal effects upon cessation. Paroxetine is well tolerated in most patients with a similar adverse effect profile to other members of its drug class. The controlled release formulation was designed to decrease the likelihood of nausea that is sometimes associated with paroxetine.[L7700,L7742]
Prasugrel, a thienopyridine derivative, is a platelet activation and aggregation inhibitor structurally and pharmacologically related to clopidogrel and ticlopidine. Similar to clopidogrel, prasugrel is a prodrug that requires enzymatic transformation in the liver to its active metabolite, R-138727. R-138727 irreversibly binds to P2Y12 type ADP receptors on platelets thus preventing activation of the GPIIb/IIIa receptor complex. As a result, inhibition of ADP-mediated platelet activation and aggregation occurs. Prasugrel was developed by Daiichi Sankyo Co. and is currently marketed in the United States and Canada in cooperation with Eli Lilly and Company for acute coronary syndromes planned for percutaneous coronary intervention (PCI). FDA approved in 2009.
Paroxetine {u} (Compound) binds {v} (Gene) CYP2B6
CYP2B6 {u} (Gene) is bound by {v} (Compound) Prasugrel
Paroxetine {u} (Compound) causes {v} (Side Effect) Hypersensitivity
Hypersensitivity {u} (Side Effect) is caused by {v} (Compound) Prasugrel
Paroxetine {u} (Compound) binds {v} (Gene) CYP2B6
CYP2B6 {u} (Gene) is bound by {v} (Compound) Halothane
Halothane {u} may cause a minor interaction that can limit clinical effects when taken with {v} Prasugrel
Paroxetine {u} (Compound) causes {v} (Side Effect) Hypersensitivity
Hypersensitivity {u} (Side Effect) is caused by {v} (Compound) Cimetidine
Cimetidine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Prasugrel
Paroxetine {u} (Compound) causes {v} (Side Effect) Retinal haemorrhage
Retinal haemorrhage {u} (Side Effect) is caused by {v} (Compound) Pentosan polysulfate
Pentosan polysulfate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Prasugrel
Paroxetine {u} (Compound) downregulates {v} (Gene) UBE2S
UBE2S {u} (Gene) is regulated by {v} (Gene) P2RY12
P2RY12 {u} (Gene) is bound by {v} (Compound) Prasugrel
Paroxetine {u} (Compound) downregulates {v} (Gene) UBE2S
UBE2S {u} (Gene) is downregulated by {v} (Compound) Ponatinib
Ponatinib {u} may lead to a major life threatening interaction when taken with {v} Prasugrel
Paroxetine {u} (Compound) downregulates {v} (Gene) DNM1L
DNM1L {u} (Gene) is downregulated by {v} (Compound) Bromfenac
Bromfenac {u} may lead to a major life threatening interaction when taken with {v} Prasugrel
Paroxetine {u} (Compound) causes {v} (Side Effect) Haematoma
Haematoma {u} (Side Effect) is caused by {v} (Compound) Ticagrelor
Ticagrelor {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Prasugrel
Paroxetine {u} (Compound) downregulates {v} (Gene) COTL1
COTL1 {u} (Gene) is downregulated by {v} (Compound) Cimetidine
Cimetidine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Prasugrel
Paroxetine (Compound) binds CYP2B6 (Gene) and CYP2B6 (Gene) is bound by Prasugrel (Compound)
Paroxetine (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Prasugrel (Compound)
Paroxetine (Compound) binds CYP2B6 (Gene) and CYP2B6 (Gene) is bound by Halothane (Compound) and Halothane may cause a minor interaction that can limit clinical effects when taken with Prasugrel
Paroxetine (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Cimetidine (Compound) and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Prasugrel
Paroxetine (Compound) causes Retinal haemorrhage (Side Effect) and Retinal haemorrhage (Side Effect) is caused by Pentosan polysulfate (Compound) and Pentosan polysulfate may cause a moderate interaction that could exacerbate diseases when taken with Prasugrel
Paroxetine (Compound) downregulates UBE2S (Gene) and UBE2S (Gene) is regulated by P2RY12 (Gene) and P2RY12 (Gene) is bound by Prasugrel (Compound)
Paroxetine (Compound) downregulates UBE2S (Gene) and UBE2S (Gene) is downregulated by Ponatinib (Compound) and Ponatinib may lead to a major life threatening interaction when taken with Prasugrel
Paroxetine (Compound) downregulates DNM1L (Gene) and DNM1L (Gene) is downregulated by Bromfenac (Compound) and Bromfenac may lead to a major life threatening interaction when taken with Prasugrel
Paroxetine (Compound) causes Haematoma (Side Effect) and Haematoma (Side Effect) is caused by Ticagrelor (Compound) and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Prasugrel
Paroxetine (Compound) downregulates COTL1 (Gene) and COTL1 (Gene) is downregulated by Cimetidine (Compound) and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Prasugrel